This recent Cochrane review of randomized controlled trials comparing the transfusion of pathogen-reduced platelets with standard platelets suggests no evidence of a difference in the incidence of clinically significant bleeding complication or all-cause mortality. The review also highlighted high-quality evidence showing that pathogen-reduced platelet transfusions increase the risk of platelet refractoriness and platelet transfusion requirements. Longitudinal studies are needed for both products and their use in neonates as well as older children. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Ruchika Goel and Cassandra D. Josephson.